Opendata, web and dolomites

ARREST BLINDNESS SIGNED

Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ARREST BLINDNESS project word cloud

Explore the words cloud of the ARREST BLINDNESS project. It provides you a very rough idea of what is the project "ARREST BLINDNESS" about.

gmp    scarring    epithelial    millions    therapy    cell    translating    cells    quality    validation    clinic    components    society    translation    situations    lag    corneal    blind    collagen    restore    neural    image    hindering    over    supply    dystrophy    regress    thinning    treatments    actively    therapies    human    transparency    visually    blood    risk    validate    standardized    technologies    treatable    gene    spectrum    implant    scarce    cornea    vessels    evaluation    fabricated    bio    endothelial    lymphatic    alleviate    engineered    models    transplantable    clinical    lack    disorders    stroma    follow    stem    immune    regenerative    tremendous    bioengineered    privilege    scaffold    scaffolds    artificial    preclinical    postoperative    globally    unnecessarily    compliant    stromal    preparation    productivity    tissue    trauma    europeans    stages    blinding    operative    million    function    additionally    worldwide    regenerate    donor    therapeutic    proof    organs    monitor    cycle    blindness    impaired    arrest    either    medicine    life    replace   

Project "ARREST BLINDNESS" data sheet

The following table provides information about the project.

Coordinator
LINKOPINGS UNIVERSITET 

Organization address
address: CAMPUS VALLA
city: LINKOPING
postcode: 581 83
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.arrestblindness.eu
 Total cost 6˙030˙052 €
 EC max contribution 5˙993˙177 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LINKOPINGS UNIVERSITET SE (LINKOPING) coordinator 1˙623˙175.00
2    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 1˙122˙407.00
3    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 738˙065.00
4    NETHERLANDS INSTITUTE FOR INNOVATIVE OCULAR SURGERY NL (ROTTERDAM) participant 622˙582.00
5    UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE ES (ELCHE) participant 397˙656.00
6    LINKOCARE LIFE SCIENCES AB SE (LINKOPING) participant 321˙278.00
7    OPTOMEDICAL TECHNOLOGIES GMBH DE (LUBECK) participant 281˙222.00
8    AEON ASTRON EUROPE B.V. NL (LEIDEN) participant 277˙075.00
9    AARHUS UNIVERSITET DK (AARHUS C) participant 237˙165.00
10    NOVALIQ GMBH DE (HEIDELBERG) participant 149˙250.00
11    LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AT (WIEN) participant 142˙800.00
12    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 80˙500.00
13    GENE SIGNAL INTERNATIONAL SA CH (LAUSANNE) participant 0.00

Map

 Project objective

Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medicine therapies to the clinic. The objective of ARREST BLINDNESS is therefore to develop and validate new regenerative-based therapies addressing a spectrum of blinding disorders of the cornea. These conditions either have no effective current treatments, depend on a scarce supply of donor tissue, or non-standardized methods are hindering validation of promising regenerative treatments. To achieve our objective, we will implant GMP-fabricated collagen-based bioengineered scaffolds to replace or regenerate the corneal stroma in cases of stromal thinning, scarring, dystrophy or trauma; deliver therapeutic epithelial stem and endothelial cells to the cornea to restore its transparency; deliver regenerative factors to promote neural growth and function; and actively maintain corneal immune privilege in high-risk situations by targeted therapeutic approaches to regress blood and lymphatic vessels. We will additionally develop advanced methods to image and monitor therapy throughout the cycle from GMP-compliant cell and scaffold preparation through the pre- and intra-operative stages, to postoperative follow-up and evaluation. After proof-of-concept and preclinical validation of key enabling components, these technologies will be used by one or several partners in preclinical models and in phase I/II human clinical studies. ARREST BLINDNESS directly addresses the translation of regenerative medicine, bio-artificial organs, tissue engineered scaffolds, and advanced cell and gene therapies into clinical use and will help to alleviate the worldwide problem of corneal blindness.

 Deliverables

List of deliverables.
First study approvals package for Phase I Biocornea study Documents, reports 2020-01-29 12:55:43
Classification of LSCD by in vivo confocal microscopy Documents, reports 2020-01-29 12:55:43
Final report on minipig study results Documents, reports 2020-01-29 12:55:43
Project website and promotional materials Websites, patent fillings, videos etc. 2020-01-29 12:55:43
Dissemination and Exploitation Strategy Websites, patent fillings, videos etc. 2020-01-29 12:55:43
All approvals package for multicenter Phase II study Documents, reports 2020-01-29 12:55:43

Take a look to the deliverables list in detail:  detailed list of ARREST BLINDNESS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Federico Bech, Omar González-González, Enol Artime, Joana Serrano, Ignacio Alcalde, Juana Gallar, Jesús Merayo-Lloves, Carlos Belmonte
Functional and Morphologic Alterations in Mechanical, Polymodal, and Cold Sensory Nerve Fibers of the Cornea Following Photorefractive Keratectomy
published pages: 2281, ISSN: 1552-5783, DOI: 10.1167/iovs.18-24007
Investigative Opthalmology & Visual Science 59/6 2020-01-29
2018 Viet Nhat Hung Le, Ann-Charlott Schneider, Rebecca Scholz, Felix Bock, Claus Cursiefen
Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-24037-3
Scientific Reports 8/1 2020-01-29
2018 Yanhong Hou, Viet Nhat Hung Le, Gábor Tóth, Sebastian Siebelmann, Jens Horstmann, Tim Gabriel, Felix Bock, Claus Cursiefen
UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival
published pages: 2873-2884, ISSN: 1600-6135, DOI: 10.1111/ajt.14874
American Journal of Transplantation 18/12 2020-01-29
2018 Daniele Spinozzi, Alina Miron, Marieke Bruinsma, Isabel Dapena, Itay Lavy, Perry S. Binder, Mehrdad Rafat, Silke Oellerich, Gerrit R.J. Melles
Evaluation of the Suitability of Biocompatible Carriers as Artificial Transplants Using Cultured Porcine Corneal Endothelial Cells
published pages: 1-7, ISSN: 0271-3683, DOI: 10.1080/02713683.2018.1536215
Current Eye Research 2020-01-29
2018 Sebastian Siebelmann, Paula Scholz, Simon Sonnenschein, Björn Bachmann, Mario Matthaei, Claus Cursiefen, Ludwig M. Heindl
Anterior segment optical coherence tomography for the diagnosis of corneal dystrophies according to the IC3D classification
published pages: 365-380, ISSN: 0039-6257, DOI: 10.1016/j.survophthal.2017.08.001
Survey of Ophthalmology 63/3 2020-01-29
2018 Viet Nhat Hung Le, Yanhong Hou, Jens Horstmann, Felix Bock, Claus Cursiefen
Novel Method to Detect Corneal Lymphatic Vessels In Vivo by Intrastromal Injection of Fluorescein
published pages: 267-271, ISSN: 0277-3740, DOI: 10.1097/ico.0000000000001444
Cornea 37/2 2020-01-29
2017 Jens Horstmann, Hinnerk Schulz-Hildebrandt, Felix Bock, Sebastian Siebelmann, Eva Lankenau, Gereon Hüttmann, Philipp Steven, Claus Cursiefen
Label-Free In Vivo Imaging of Corneal Lymphatic Vessels Using Microscopic Optical Coherence Tomography
published pages: 5880, ISSN: 1552-5783, DOI: 10.1167/iovs.17-22286
Investigative Opthalmology & Visual Science 58/13 2020-01-29
2018 M. Notara, S. Behboudifard, M. A. Kluth, C. Maßlo, C. Ganss, M. H. Frank, B. Schumacher, C. Cursiefen
UV light-blocking contact lenses protect against short-term UVB-induced limbal stem cell niche damage and inflammation
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-30021-8
Scientific Reports 8/1 2020-01-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARREST BLINDNESS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ARREST BLINDNESS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More